These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Martino G; Furlan R; Galbiati F; Poliani PL; Bergami A; Grimaldi LM; Adorini L; Comi G Mult Scler; 1998 Jun; 4(3):222-7. PubMed ID: 9762678 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Ruffini F; Furlan R; Poliani PL; Brambilla E; Marconi PC; Bergami A; Desina G; Glorioso JC; Comi G; Martino G Gene Ther; 2001 Aug; 8(16):1207-13. PubMed ID: 11509953 [TBL] [Abstract][Full Text] [Related]
11. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Butti E; Bergami A; Recchia A; Brambilla E; Del Carro U; Amadio S; Cattalini A; Esposito M; Stornaiuolo A; Comi G; Pluchino S; Mavilio F; Martino G; Furlan R Gene Ther; 2008 Apr; 15(7):504-15. PubMed ID: 18239607 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. Furlan R; Pluchino S; Martino G Curr Opin Neurol; 2003 Jun; 16(3):385-92. PubMed ID: 12858077 [TBL] [Abstract][Full Text] [Related]
13. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Baker D; Hankey DJ Gene Ther; 2003 May; 10(10):844-53. PubMed ID: 12732870 [TBL] [Abstract][Full Text] [Related]
14. The ependymal route for insulin-like growth factor-1 gene therapy in the brain. Hereñú CB; Sonntag WE; Morel GR; Portiansky EL; Goya RG Neuroscience; 2009 Sep; 163(1):442-7. PubMed ID: 19531373 [TBL] [Abstract][Full Text] [Related]
15. CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Slaets H; Hendriks JJ; Van den Haute C; Coun F; Baekelandt V; Stinissen P; Hellings N Mol Ther; 2010 Apr; 18(4):684-91. PubMed ID: 20068552 [TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Zlokovic BV; Apuzzo ML Neurosurgery; 1997 Apr; 40(4):805-12; discussion 812-3. PubMed ID: 9092854 [TBL] [Abstract][Full Text] [Related]
17. Transcriptome analysis of the ependymal barrier during murine neurocysticercosis. Mishra PK; Teale JM J Neuroinflammation; 2012 Jun; 9():141. PubMed ID: 22731103 [TBL] [Abstract][Full Text] [Related]
18. The virtues and vices of harnessing HSV vectors for CNS autoimmunity modulation. Hukkanen V; Nygårdas M Immunotherapy; 2013 Sep; 5(9):911-3. PubMed ID: 23998724 [No Abstract] [Full Text] [Related]
19. Exploring the Role of Gene Therapy for Neurological Disorders. Puranik N; Yadav D; Chauhan PS; Kwak M; Jin JO Curr Gene Ther; 2021; 21(1):11-22. PubMed ID: 32940177 [TBL] [Abstract][Full Text] [Related]
20. Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis. Islam MA; Kundu S; Hassan R Curr Gene Ther; 2020; 19(6):376-385. PubMed ID: 32141417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]